When you engage AbbVie Contract Manufacturing, you’re getting more than a CMO. You fully access the capabilities of a highly experienced biopharmaceutical company. You know that your project will benefit from our broad range of capabilities and portfolio of state-of-the-art facilities in North America and Europe. Most of all, you know that your project will be reliably served by a business with a trusted reputation for innovation, reliability, compliance and delivery.

AbbVie Contract Manufacturing has over 40 years of experience as a pharmaceutical developer and manufacturer. We help domestic and global companies develop, scale, and commercially manufacture pharmaceutical products drawing on our extensive experience to accelerate time to market. Our services are comprised of:

Biologics | ADC | Potent | Drug Product | Fermentation | Hot Melt Extrusion | Sterile Fill/Finish | Pre-filled Syringe | APIs

As an embedded CMO, AbbVie Contract Manufacturing allows greater access to global manufacturing and a variety of scales and technologies. We handle your pharmaceutical products with the same dedication as our own and our partners realize the unique benefits of trusting a leading biopharmaceutical company with their contract manufacturing needs.

Above all, your project will benefit from a premier scientific team with the experience to meet complex challenges with demonstrative successful proven solutions.

As a multi-year recipient of Life Science Leader annual CMO leadership award for quality, innovation, productivity and reliability, AbbVie is ready to bring our experience to your business.


AbbVie has a 125-year history of patient care, as well as a focus on developing advanced therapies to address some of the world’s most complex disease states.

AbbVie’s expanded focus on biologics and targeted medicine allows us to use our knowledge and expertise to address difficult conditions that affect significant patient populations. Our priority is our patients, helping them lead healthier lives.

Founded on January 1 of 2013, AbbVie is a renowned biopharmaceutical company that began as part of the pharmaceutical leader, Abbott, which was founded in 1888 by Dr. Wallace Abbott to provide better care for patients.

At AbbVie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today — a global biopharmaceutical company that has the ability to discover and advance innovative therapies while meeting the health needs of people and societies around the globe.


Sterile Fill/Finish Sterile Fill/Finish

AbbVie’s new aseptic fill / finish vial line located in Sligo, northwest Ireland, is approximately 130 miles from Dublin. This state-of-the-art line supports lyophilization for potent and biologics along with liquid fill vials. Equipment installation is underway with production commencing H2 2020.

Contract Manufacturing Capabilities Contract Manufacturing Capabilities

Ten state-of-the-art commercial manufacturing facilities in North America and Europe. AbbVie Contract Manufacturing offers a wide range of global contract manufacturing capabilities.

Contract Fermentation Services Contract Fermentation Services

Fermentation is a critical step in both drug and toll manufacturing, as companies look to produce the core compounds that form their eventual products. While it is possible to undertake this in-house, the expertise contract fermentation services provide can improve the quality, affordability, speed and scalability of your program.

Biologics CMO Biologics CMO

With patients’ lives at the end of the pipeline, biologics contract manufacturing needs to be safe, reliable and consistent in supply. The developers of these large molecule drugs, however, are also operating in a highly competitive space. Speed-to-market is imperative, along with efficient processes and low costs. A lot of this will rest on the quality of the cell line development and the expertise of the biologics CMO you choose.

Antibody Drug Conjugates Antibody Drug Conjugates

When selecting AbbVie Contract Manufacturing, you are partnering with a leading developer and manufacturer focused on accelerating and mitigating risks to program timelines and on efficiently fast-tracking your program to completion. AbbVie’s mAb and ADC state-of-the-art facility and expert scientific team are located in Worcester, Massachusetts, where we specialize in treating your product as our own and have demonstrated the capability to optimize success from innovation through commercialization. In addition to our expertise, our customers also benefit from a simplified supply chain as both mAb and conjugation manufacturing are conveniently located at one site.

Prefilled Syringe Manufacturing Prefilled Syringe Manufacturing

Fill-finish syringe manufacturing is one of the last steps in pharmaceutical commercialization. The goal here is efficiency and sterility. Companies don’t want to waste any of their carefully developed product and they don’t want to distribute poor quality prefilled syringes or contaminated formulas. Once established, high syringe manufacturing standards must then be maintained throughout the drug’s life span, to deliver a reliable supply for patients.



1 N Waukegan Rd.

North Chicago, IL 60064


Phone: 847-938-8524


  • CMC Strategies For The Acceleration Of Commercial-Ready ADC Manufacturing
    CMC Strategies For The Acceleration Of Commercial-Ready ADC Manufacturing

    The potential for antibody-drug conjugate (ADC) programs to accelerate from early to late stage clinical development highlights the need to establish commercial launch-ready manufacturing early and efficiently.

  • Selecting A CMO: Top Considerations
    Selecting A CMO: Top Considerations

    Choosing the right contract organization to handle the development and manufacturing of a drug product is of critical importance. You’re putting your supply chain, your brand’s reputation, and patient safety in a partner’s hands. Here are some tips to increase confidence in your decision and ensure a successful outcome.

  • AbbVie Contract Manufacturing Wins Life Science Leader CMO Awards For The Seventh Year
    AbbVie Contract Manufacturing Wins Life Science Leader CMO Awards For The Seventh Year

    “AbbVie is honored to be recognized once again as a top Contract Manufacturer by Life Science Leader,” said Azita Saleki-Gerhardt, Ph.D., President, Operations. “It is a privilege to achieve the top ranking in all six award criteria for the fourth year in a row. We are extremely proud of this achievement, as it recognizes our efforts to provide the highest quality and consistent support and services for our partners and their patients.”

  • Is Your CMO Ready For Serialization And Aggregation?
    Is Your CMO Ready For Serialization And Aggregation?

    Many companies have recognizied the inevitability of traceability, serialization, and aggregation requirements, but what plans and efforts does your CMO have dedicated to these critical initiatives?

  • Using A CMO To Streamline Process Characterization
    Using A CMO To Streamline Process Characterization

    While traditional small molecule drug products usually consist of pure chemical substances that are easily analyzed after manufacture, biologics such as monoclonal antibodies (mAbs) are much more complex. 

  • Tackling The Challenges Of Biologics Development And Manufacturing
    Tackling The Challenges Of Biologics Development And Manufacturing

    Biologics offer distinct advantages that small molecule drugs do not, but they are far more complex to develop and manufacture. Read why it is critical to have the right manufacturing partner to minimize challenges as a therapy moves from discovery to commercialization.

  • Small Molecule Impurities Represent A Key Challenge When Designing Control Systems For ADC Therapeutic Manufacture
    Small Molecule Impurities Represent A Key Challenge When Designing Control Systems For ADC Therapeutic Manufacture

    Composed of both antibody and small molecule elements, ADCs have a complex structure from which many different impurities can arise. Drawing on existing ICH guidelines, a recent publication co-authored by AbbVie suggests a science-based approach that can be applied to the design of an effective control strategy for small molecule impurities in ADC therapeutics.